Fibromyalgia Trial, Recruiting NCT07226648 Sponsor: SPIRE Therapeutics Inc. Condition: Fibromyalgia
Back to Fibromyalgia

Fibromyalgia Trial, Recruiting

NCT07226648
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give their formal agreement to take part in the study.
  • People who are 22 years of age or older.
  • People who have been diagnosed with fibromyalgia according to the 2016 American College of Rheumatology criteria, which includes widespread pain across at least 4 of 5 body regions, specific pain and symptom scores meeting set thresholds, and symptoms present at a similar level for at least 3 months.
  • People for whom at least two standard fibromyalgia medications (such as pregabalin, duloxetine, or milnacipran) have not worked well enough.
  • People who have tried at least one physical or talking-based therapy for fibromyalgia without adequate relief — this includes a wide range of options such as aerobic exercise, hydrotherapy, yoga, massage, Tai Chi, Pilates, physiotherapy techniques, heat or cold therapy, mindfulness, mirror therapy, graded motor imagery, or cognitive behavioural therapy (CBT), among others.
  • People whose pain score is 4 or higher on an 11-point pain scale (where 0 is no pain and 10 is the worst pain) at the initial screening visit.
  • People whose pain score averages 4 or higher on that same scale across 3 days in a row before the study begins.
  • People who are willing and able to follow all study procedures throughout the trial.
  • People who have been on the same mental health treatment (such as medication or therapy) for at least one month before screening and are willing to stay on that same treatment for the duration of the study, unless a change is recommended by the trial doctor.
  • People who could potentially become pregnant must have a negative pregnancy test at screening and must agree to use a highly effective form of contraception during the study (such as an IUD, tubal ligation, vasectomized partner, or long-acting contraceptive with a less than 1% chance of pregnancy).

Who may not be able to join:

  • People who have ever been diagnosed with bipolar disorder or a schizophrenia-related condition at any point in their life.
  • People who have had a moderate or severe alcohol or drug use disorder in the past 6 months.
  • People who have had an unstable diagnosis of obsessive-compulsive disorder (OCD) or post-traumatic stress disorder (PTSD) in the past 30 days, as determined by the trial doctor.
  • People who have had a primary diagnosis of anorexia nervosa, bulimia nervosa, or binge eating disorder in the past 3 months.
  • People with a clinically significant neurodevelopmental, cognitive, or personality disorder, as assessed by the trial doctor.
  • People assessed as being at moderate or high risk of suicide, based on a standard screening tool or the trial doctor's judgement.
  • People who have a lifetime history of a serious suicide attempt, in the medical opinion of the trial doctor.
  • People whose pain treatment has changed in the past 2 months.
  • People who have received electroconvulsive therapy, transcranial magnetic stimulation, ketamine, or esketamine in the past 30 days.
  • People with a progressive neurological disease such as multiple sclerosis, a brain or spinal cord tumour, or severe spinal stenosis.
  • People whose pain is caused by cancer.
  • People diagnosed with a cancer (other than certain minor skin cancers) within the past five years, or with a life expectancy of less than one year due to advanced cancer.
  • People whose pain is caused by an autoimmune condition.
  • People with a general medical condition that is not adequately managed, in the opinion of the trial doctor.
  • People with a lifetime history of small vessel disease in the brain.
  • People with a lifetime history of bleeding inside the skull (intracranial haemorrhage).
  • People who are currently pregnant or breastfeeding.
  • People who have a medical device implanted in their head or neck.
  • People who are unable to have an MRI scan or who cannot tolerate the procedure.
  • People who have previously taken part in a DIADEM clinical trial (note: people who were screened but did not proceed may be rescreened once).
  • People with any other medical or psychiatric history, condition, or circumstance that the trial doctor believes could affect their ability to participate safely or could affect the reliability of the study results.
  • People with braids, dreadlocks, or other hairstyles that block access to the side of the head, who are unwilling to temporarily adjust their hairstyle for the procedure.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Akiko Okifuji, PhD, University of Utah

Phone: 801-585-7690

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
SPIRE Therapeutics Inc.
Registry
ClinicalTrials.gov
Start date
11 December 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Numerical Rating Scale - 11 (NRS-11) pain score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov